content: SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
               ------------------------------------------------------
  
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): November 6, 2003
                                                           ----------------
  
                                 CYTOGEN CORPORATION
               ------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                       000-14879                222322400
  ----------------------------     ------------------------    -------------------
  (State or Other Jurisdiction     (Commission File Number)     (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ               08540
  ---------------------------------------------------------             ----------
        (Address of Principal Executive Offices)                        (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  
  <PAGE>
  
  
  ITEM 5.    OTHER EVENTS.
  
           On October 29, 2003, Cytogen  Corporation,  a Delaware corporation (the
  "Company")   filed  a  registration   statement  (File  No.   333-110040)   (the
  "Registration   Statement")  on  Form  S-3  with  the  Securities  and  Exchange
  Commission (the  "Commission")  relating to the public offering pursuant to Rule
  415 under the  Securities  Act of 1933,  as amended,  of up to an  aggregate  of
  $60,000,000 in shares of common stock of the Company.  The  Commission  declared
  the Registration Statement effective on October 30, 2003.
  
           On  November  6,  2003,  the  Company  entered  into a  Share  Purchase
  Agreement (the "Share Purchase Agreement") with certain institutional  investors
  pursuant to which the Company  issued and sold an aggregate of 1,863,637  shares
  of its common  stock at a purchase price of $11.00 per share for aggregate gross
  proceeds of $20.5 million.
  
           A copy of each of the Share  Purchase  Agreement  and the related press
  release of the Company,  dated  November 7, 2003, are filed herewith as Exhibits
  10.1 and 99.1,  respectively,  and are  incorporated  herein by  reference.  The
  foregoing  description  of the  issuance  of  Common  Stock  by the  Company  is
  qualified in its entirety by reference to such Exhibits.
  
  ITEM 7.    FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
  
        (c)    Exhibits.
  
                 Exhibit No.     Description
                 -----------     -----------
                    10.1         Share Purchase Agreement by and among the Company
                                 and the Purchasers dated November 6, 2003.
  
                    99.1         Press release of the Company dated November 7,
                                 2003.
  
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                    CYTOGEN CORPORATION
  
  
                                    By:  /s/ Michael D. Becker
                                         -------------------------------------
                                         Michael D. Becker
                                         President and Chief Executive Officer
  
  
  Dated:   November 7, 2003
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
          Exhibit No.      Description
          -----------      -----------
  
             10.1          Share Purchase  Agreement by and among the Company and
                           the Purchasers dated November 6, 2003.
  
             99.1          Press release of the Company dated November 7, 2003.
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k110603.txt", "description": "FORM 8-K DATED NOVEMBER 6, 2003", "secsgml_size_bytes": 4169}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2835", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "03984993"}, "business-address": {"street1": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "600 COLLEGE RD EAST CN 5308", "street2": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
               ------------------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): November 6, 2003
                                                           ----------------
  
                                 CYTOGEN CORPORATION
               ------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                       000-14879                222322400
  ----------------------------     ------------------------    -------------------
  (State or Other Jurisdiction     (Commission File Number)     (I.R.S. Employer
        of Incorporation)                                      Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ               08540
  ---------------------------------------------------------             ----------
        (Address of Principal Executive Offices)                        (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  ITEM 5.    OTHER EVENTS.
  
           On October 29, 2003, Cytogen  Corporation,  a Delaware corporation (the
  "Company")   filed  a  registration   statement  (File  No.   333-110040)   (the
  "Registration   Statement")  on  Form  S-3  with  the  Securities  and  Exchange
  Commission (the  "Commission")  relating to the public offering pursuant to Rule
  415 under the  Securities  Act of 1933,  as amended,  of up to an  aggregate  of
  $60,000,000 in shares of common stock of the Company.  The  Commission  declared
  the Registration Statement effective on October 30, 2003.
  
           On  November  6,  2003,  the  Company  entered  into a  Share  Purchase
  Agreement (the "Share Purchase Agreement") with certain institutional  investors
  pursuant to which the Company  issued and sold an aggregate of 1,863,637  shares
  of its common  stock at a purchase price of $11.00 per share for aggregate gross
  proceeds of $20.5 million.
  
           A copy of each of the Share  Purchase  Agreement  and the related press
  release of the Company,  dated  November 7, 2003, are filed herewith as Exhibits
  10.1 and 99.1,  respectively,  and are  incorporated  herein by  reference.  The
  foregoing  description  of the  issuance  of  Common  Stock  by the  Company  is
  qualified in its entirety by reference to such Exhibits.
  
  ITEM 7.    FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
  
        (c)    Exhibits.
  
                 Exhibit No.     Description
                 -----------     -----------
                    10.1         Share Purchase Agreement by and among the Company
                                 and the Purchasers dated November 6, 2003.
  
                    99.1         Press release of the Company dated November 7,
                                 2003.
  SIGNATURES
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                    CYTOGEN CORPORATION
  
                                    By:  /s/ Michael D. Becker
                                         -------------------------------------
                                         Michael D. Becker
                                         President and Chief Executive Officer
  
  Dated:   November 7, 2003
  EXHIBIT INDEX
  
          Exhibit No.      Description
          -----------      -----------
  
             10.1          Share Purchase  Agreement by and among the Company and
                           the Purchasers dated November 6, 2003.
  
             99.1          Press release of the Company dated November 7, 2003.